stockrow
Friday 6 November 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +200.5%
Quarter to September 2026, against a year earlier
12.19
1.17
+10.62%
Follow VIR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.25 | 5.64 | 20.16 | 12.18 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.84) | 13.86 | (9.97) | (32.28) | |
P/B ratio |
2.11 | 1.74 | 1.62 | 1.09 | |
Price to Tangible BV |
2.17 | 1.78 | 1.68 | 1.13 | |
EV/Sales |
4.73 | 3.87 | 12.86 | 5.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.16) | (5.80) | (1.89) | (0.94) | |
EV/FCF |
(10.09) | (5.77) | (1.87) | (0.92) | |
Quick Ratio |
5.71 | 5.63 | 6.50 | 5.05 | |
Current Ratio |
6.30 | 6.04 | 7.11 | 5.54 | |
Net Debt/EBITDA |
4.48 | (6.98) | 3.70 | 10.79 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.25 | 0.06 | 0.06 | |
Operating CF/Net income |
1.10 | 1.54 | 1.05 | 0.60 | |
Capex/Depreciation |
(0.02) | (0.01) | (0.12) | (0.10) | |
Research and Development Expense of Revenue |
(42,574.47%) | 56.62% | (375,593.10%) | 137.89% | |
Selling, General and Administrative Expense of Revenue |
(12,994.68%) | 12.64% | (80,479.31%) | 36.86% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
(5,561.17%) | 5.19% | (41,679.31%) | 17.49% | |
Graham Net Nets |
0.15 | 0.20 | 0.23 | 0.33 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.17%) | (18.16%) | (34.93%) | (52.40%) | |
Free Cash Flow Yield |
(7.50%) | (11.92%) | (34.06%) | (47.45%) | |
Revenue per Share |
0.00 | 1.42 | 0.00 | 0.46 | |
Operating CF per Share |
(0.63) | 0.74 | (0.90) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.63) | 0.74 | (0.90) | (0.19) | |
Cash per Share |
2.72 | 3.19 | 3.25 | 3.39 | |
Shareholders Equity per Share |
5.29 | 5.86 | 5.52 | 5.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.29 | 5.86 | 5.52 | 5.52 | |
Free Cash Flow |
(106.11) | 123.29 | (132.78) | (26.33) | |
Working Capital |
427.61 | 478.78 | 449.43 | 421.27 | |
Capital Expenditures |
(0.03) | (0.03) | (0.39) | (0.46) | |
Net Current Asset Value |
292.45 | 341.43 | 310.17 | 276.53 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.18) | 0.00 | (13.45) | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
9.09 | 14.99 | 4.59 | 7.44 | |
Average Assets |
1,065.65 | 1,203.67 | 1,166.66 | 1,200.82 | |
Average Common Equity |
846.07 | 964.98 | 928.29 | 957.83 |
Columns are period end dates · fundamentals updated 6 Nov 2026